Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Dosimetry
6034
Poster (digital)
Physics
Dosimetric comparison of Intraoperative Radiotherapy and SRS for liver metastases
Davide Scafa, Germany
PO-1530

Abstract

Dosimetric comparison of Intraoperative Radiotherapy and SRS for liver metastases
Authors:

Davide Scafa1, Gustavo R. Sarria1, Frank A. Giordano1, David Koch1, Thomas Muedder1, Jasmin A. Holz1, Younéss Nour1, Stephan Garbe1, Maria A. Gonzalez-Carmona2, Georg Feldmann3, Tim O. Vilz4, Mümtaz Köksal1, Leonard Christopher Schmeel1

1University Hospital Bonn, Department of Radiation Oncology, Bonn, Germany; 2University Hospital Bonn, Department of Internal Medicine I, Bonn, Germany; 3University Hospital Bonn, Department of Internal Medicine III, Bonn, Germany; 4University Hospital Bonn, Department of Surgery, Bonn, Germany

Show Affiliations
Purpose or Objective

Purpose/Objectives

To perform a dosimetric comparison between kilovoltage intraoperative radiotherapy (IORT) and stereotactic radiosurgery (SRS) simulating both deep-inspiration breath-hold (DIBH) and free-breathing (FB) modalities for patients with liver metastases.

Material and Methods
Results

Results

Eight patients encompassing 10 lesions were included in the study. The mean liver volume was 2,050.97 cm3(SD 650.82) and mean GTV volume 12.23 cm3 (SD 12.62). As for target structures, GTV-IORT (19.44 cm3 [SD 17.26]) were significantly smaller than both PTV DIBH-SRS (30.74 cm3 [SD 24.64], p=0.002) and PTV FB-SRS (75.82 cm3 [SD 45.65], p=0.002). The median applicator size was 3 cm (1.5 – 4.5) and the mean IORT simulated delivery time was 45.45 min (SD 19.88). All constraints were met in all modalities. Liver V9.1 showed significantly smaller volumes with IORT (63.39 cm3 [SD 35.67]) when compared to DIBH-SRS (150.12 cm3[SD 81.43], p=0.002) or FB-SRS (306.13 cm3 [SD 128.75], p=0.002). No other statistical or dosimetrically relevant difference was observed for stomach, spinal cord or biliary tract. Mean IORT D90 was 85.3% (SD 6.05), whereas D95 for DIBH-SRS and FB-SRS were 99.03% (SD 1.71, p=0.042) and 98.04% (SD 3.46) p=0.036), respectively.

Conclusion

Conclusion

Kilovoltage IORT bears the potential as novel add-on treatment for resectable liver metastases, significantly reducing healthy liver exposure to radiation in comparison to SRS. Prospective clinical evidence is required to confirm this hypothesis.